Dashboard/EDIT/reni-cel/event

ReadoutTopline Readout

reni-cel RUBY Phase 1/2 SCD Update at ASH 2026

EDIT·reni-cel·Sickle Cell Disease·

Phase 3

·NCT05444894

current best date

DEC

2026

MONTH7 months

Takeaway

Updated Phase 1/2 reni-cel data in sickle cell disease at ASH 2026. Approved benchmark in the same indication: CASGEVY (CRSP/Vertex). Watch: VOC reduction, fetal hemoglobin %, time to engraftment, safety.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~58%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoACRISPR/Cas12a HBG1/2 promoter edit

Reni-cel is Editas Medicine's ex vivo gene-editing therapy for sickle cell disease and beta thalassemia that uses CRISPR/Cas12a — rather than the more common Cas9 — to edit patient-derived blood stem cells and reactivate fetal hemoglobin production. After the edited cells are reinfused following conditioning chemotherapy, elevated fetal hemoglobin compensates for defective adult globin, preventing red blood cell sickling and reducing transfusion dependence. Editas positions reni-cel as a next-generation alternative to CASGEVY, with the hypothesis that Cas12a provides a distinct precision profile at the BCL11A enhancer locus.

Indication

Oncology - Heme

Sickle Cell Disease

MeSH · D000755

No primer in glossary yet.

Trial

active

NCT05444894 ↗

RUBY Phase 1/2 Reni-cel in SCD

Glossary · what this readout is measuring

1 term detected in the takeaway

ASHconference
American Society of Hematology Annual Meeting
The major heme/onc meeting (~30,000 attendees). Early-December; key venue for blood cancer and rare hematology readouts.

Sector base rates · reference data

historical record · not prediction

of 1 historical Phase 3 readouts in Oncology - Heme: 1 positive, 0 mixed, 0 negative.

Positive

1/ 1

100%

Mixed

0/ 1

Negative

0/ 1

positive rate 100% · primary endpoint hit rate 100%

Reference data · comparable readouts

How Ph3 readouts in Oncology - Heme have landed.

Reference, not prediction. We surface the historical record so you can read it yourself. We never extrapolate to the upcoming event.

Positive

1/1

100% in record

Primary endpoint hit

100%

across 1 readouts

Drug · sponsorPhase · yearOutcomeKey metricSource

pirtobrutinib (BRUIN-321)

LLY · CLL

Ph3 · Dec 2024positivePFS HR 0.54PR

mosunetuzumab

RHHBY · r/r FL

Ph2 · Jun 2022positiveCR rate 60%conference

sorted by phase match, then recency · sources span PR wires, CT.gov, FDA notices, and conference presentations · we never editorialize the outcome label

Competitive landscape

4 peers in Oncology - Heme · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Next catalyst
BEAM-101	BEAM	cell therapy	base editing of HBG1/2 to reactivate fetal hemoglobin	READOUT · Dec 26
CASGEVYexagamglogene autotemcel	CRSP	cell therapy	CRISPR/Cas9 BCL11A enhancer edit	CONFERENCE · Dec 26
CB-010	CRBU	cell therapy	allogeneic CRISPR-edited anti-CD19 CAR-T	CONFERENCE · May 26
JAKAFIruxolitinib	INCY	small molecule	JAK1/JAK2 inhibitor	READOUT · Sep 26

Prior EDIT reactions to Readout events

1 historical event · base rate, not prediction

Median 1W move

-27.2%

Median 1M move

-16.6%

Positive outcomes

0/ 1

Negative outcomes

1/ 1

100%

Date	Headline	Outcome	1W	1M	6M
Oct 2023	reni-cel — Phase 3 Topline — Mixed Result	negative	-27.2%	-16.6%	-34.8%

Historical EDIT stock reaction to past Readout catalysts. Past performance is not a forecast — base rates anchor expectations, not outcomes. Positive rate 0%.

Disclosure trail

1 observation · sorted by confidence

Apr 12, 2026·18d agopinned · highest confidence
MED confPR
top claim
DEC2026
MONTH
“Editas plans to present an updated dataset from the RUBY Phase 1/2 study of reni-cel in sickle cell disease at ASH 2026 in December.”
conf 84%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.